Brooks Laboratories Ltd

AGM Details

• AGM scheduled for 3 September 2026 at 9:00 AM IST via VC/OAVM.
• Addendum dated 21 August 2026 clarifies Resolution No. 4.

Resolutions proposed

• Resolution 2 (Ordinary): adopt Annual Report 2025-26.
• Resolution 4 (Special): modify related party transactions and corporate guarantees; to be approved by addendum.

Related party transactions

• Addendum aligns related party arrangements with corporate guarantees.

Voting/other outcomes

• Voting results are not disclosed in the addendum.

Other material approvals

• No additional material approvals stated beyond the Resolution 4 amendment.

Financial performance

• Revenue from operations: Rs 8,573.84 lakh; up 3.85% YoY.
• Total income: Rs 8,690.89 lakh; up 4.16% YoY.
• PBDIT: Rs 823.02 lakh; improved over prior year.
• PBT: Rs 580.50 lakh; growth ~79.86%.
• PAT: Rs 577.43 lakh; growth ~90.33%.
• EPS: Rs 1.97 per share.
• Cost of materials consumed: Rs 4,961.22 lakh; employee benefits Rs 1,516.21 lakh.
• Finance costs: Rs 83.53 lakh; depreciation: Rs 158.99 lakh.
• Net cash from operating activities: Rs 929.34 lakh.

Operations & growth

• Materials cost reduced; procurement efficiency improving gross margins.
• Employee benefits rose to Rs 1,516.21 lakh amid manpower expansion.
• SPOT tenders secured; Lebanon and Sudan opportunities executed.
• Export focus on semi-regulated markets; stronger international registrations.

Capital structure & liquidity

• Total debt Rs 727.76 lakh; equity Rs 12,084.40 lakh; gearing 6.02%.
• Cash and cash equivalents Rs 658.79 lakh.
• Current ratio 1.72x.
• Cash flow from operations Rs 929.34 lakh.

Dividend & capital allocation

• Dividend for FY2025-26 not recommended.
• CSR provisions not applicable; reserves unchanged.

Governance & leadership

• Jitendra Pratap Singh to be reappointed as director.
• Prashant Rathi appointed CEO from 1 June 2026; previously CFO.
• ABRIDGE SPECIALITY LIMITED incorporated on 2 July 2026.

Strategic focus & markets

• Strategy emphasizes semi-regulated markets, product registrations, Beta-lactam portfolio.
• Post-year: Brooks Steriscience stake sale; 32.67% holding.

Audit, risk & compliance

• Auditors: DMKH & Co; no qualification; IFCs adequate.
• Cost Auditor remuneration Rs 60,000 plus taxes.
• Independent directors declared independence; annual secretarial audit conducted.

Book closure and AGM details

• Book Closure: Aug 27, 2026 to Sep 3, 2026 (inclusive).
• Purpose: 24th AGM.
• E-voting cut-off date: Aug 27, 2026.
• E-voting period: Aug 31, 2026 9:00 AM IST to Sep 2, 2026 5:00 PM IST.
• AGM date: Sep 3, 2026.
• Security: Equity shares.

Financial highlights

• Standalone revenue from operations ₹2,296.08 lakh in Q1 FY27.
• Total income ₹2,313.75 lakh in Q1 FY27.
• Standalone net profit after tax ₹141.86 lakh; Basic EPS ₹0.48.
• Consolidated net profit after tax ₹-178.69 lakh; Consolidated EPS ₹-0.61.

Segment performance

• Manufacturing revenue ₹2,277.55 lakh; Trading ₹18.53 lakh in Q1 FY27.
• Standalone manufacturing profit ₹185.10 lakh; trading profit ₹-13.79 lakh.
• Total standalone segment profit ₹171.31 lakh.

Joint venture impact

• Brooks Steriscience Ltd: revenue ₹1,751.30 lakh; loss after tax ₹654.18 lakh.
• Company share of JV loss ₹320.55 lakh in Q1 FY27.

AGM and regulatory updates

• AGM 24th scheduled for 3 September 2026 at 09:00 IST via VC/OAVM.
• Annual Report 2025-26 available online at brookslabs.net; exact path annual-report.html.
• Cut-off date for email addresses: 7 August 2026.
• KYC updates under SEBI 2024 required for physical holders: PAN, address, mobile, bank details.
• Electronic payments for folios without updated KYC from April 1, 2024.
• RTA contact: MUFG Intime India Private Limited for queries.

AGM details

• AGM on 3 September 2026 at 9:00 AM IST via VC/OAVM.

Resolutions to be voted

• Resolutions include ordinary and special business as described in the notice.
• Annual Report 2025-26 to be considered.